Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipapkinogene sovacivec - Transgene

Next Previous
Drug Profile

Tipapkinogene sovacivec - Transgene

Alternative Names: MVA-HPV-IL2 vaccine; R-3484; RG 3484; RO5217790; TG 4001

Latest Information Update: 16 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transgene
  • Developer EMD Serono Research & Development Institute; Merck & Co; Roche; Transgene
  • Class Antineoplastics; Cancer vaccines; Gene therapies; Immunotherapies; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Head and neck cancer; Oropharyngeal cancer
  • Phase I/II Anal cancer; Cervical cancer; Penile cancer; Vulvovaginal cancer
  • Discontinued Cervical intraepithelial neoplasia

Most Recent Events

  • 14 Oct 2024 Updated efficacy and adverse event data from a phase II trial in anogenital cancer released by Transgene
  • 05 Jun 2023 Efficacy data from a phase II trial in Anogenital cancer released by Transgene
  • 02 Jun 2023 Efficacy and immunogenicity data from phase-Ib/II trial in Anal cancer, Penile cancer, Vulvovaginal cancer and Cervical cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top